Literature DB >> 8060919

Serum soluble IL-2 receptor (sIL-2R) and eosinophil cationic protein (ECP) levels in atopic dermatitis.

M Furue1, H Sugiyama, K Tsukamoto, N Ohtake, K Tamaki.   

Abstract

We examined the serum soluble IL-2 receptor and eosinophil cationic protein levels in patients with atopic dermatitis (n = 21), patients with urticaria (n = 12), and normal healthy individuals (n = 14). We found that both soluble IL-2 receptor levels and eosinophil cationic protein levels were significantly higher in atopic dermatitis than in urticaria or normal controls. Although both soluble IL-2 receptor levels and eosinophil cationic protein levels were significantly correlated with clinical severity scores in atopic dermatitis, the correlation between eosinophil cationic protein levels and clinical severity scores was higher than that between soluble IL-2 receptor levels and clinical severity scores. However, soluble IL-2 receptor levels, eosinophil cationic protein levels and clinical severity scores were not significantly correlated with IgE levels. The chronological changes of soluble IL-2 receptor and eosinophil cationic protein levels differ from patient to patient. However, levels of soluble IL-2 receptor and eosinophil cationic protein seem to parallel to each other in 65% of patients with AD. Measurement of serum eosinophil cationic protein or soluble IL-2 receptor levels may be a useful tool to monitor the short-term or long-term disease activity of atopic dermatitis in conjunction with clinical severity scores.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8060919     DOI: 10.1016/0923-1811(94)90081-7

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  5 in total

1.  Effect of processed foods on serum levels of eosinophil cationic protein among children with atopic dermatitis.

Authors:  Ji Min Lee; Hyun Jung Jin; Geounwoong Noh; Sang Sun Lee
Journal:  Nutr Res Pract       Date:  2011-06-21       Impact factor: 1.926

Review 2.  Specific immunotherapy in atopic dermatitis.

Authors:  Jungsoo Lee; Chang Ook Park; Kwang Hoon Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-11-25       Impact factor: 5.764

3.  EASI p-EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers.

Authors:  Daphne S Bakker; Lieneke F M Ariens; Barbara Giovannone; DirkJan Hijnen; Eveline M Delemarre; Edward Knol; Stefan Nierkens; Marjolein S de Bruin-Weller; Judith L Thijs; Julia Drylewicz
Journal:  Allergy       Date:  2020-07-24       Impact factor: 13.146

4.  The metalloprotease ADAM10 generates soluble interleukin-2 receptor alpha (sCD25) in vivo.

Authors:  Sophia Kirschke; Ireti Ogunsulire; Balachandar Selvakumar; Neele Schumacher; Tanya Sezin; Stefan Rose-John; Alexander Scheffold; Christoph Garbers; Juliane Lokau
Journal:  J Biol Chem       Date:  2022-04-07       Impact factor: 5.486

5.  Exploration of biomarkers to predict clinical improvement of atopic dermatitis in patients treated with dupilumab: A study protocol.

Authors:  Takeshi Nakahara; Kenji Izuhara; Daisuke Onozuka; Satoshi Nunomura; Risa Tamagawa-Mineoka; Koji Masuda; Susumu Ichiyama; Hidehisa Saeki; Yudai Kabata; Riichiro Abe; Mamitaro Ohtsuki; Koji Kamiya; Tatsuro Okano; Tomomitsu Miyagaki; Yozo Ishiuji; Akihiko Asahina; Hiroshi Kawasaki; Keiji Tanese; Hiroshi Mitsui; Tatsuyoshi Kawamura; Takuya Takeichi; Masashi Akiyama; Emi Nishida; Akimichi Morita; Kyoko Tonomura; Yukinobu Nakagawa; Koji Sugawara; Chiharu Tateishi; Yoko Kataoka; Rai Fujimoto; Sakae Kaneko; Eishin Morita; Akio Tanaka; Michihiro Hide; Natsuko Aoki; Shigetoshi Sano; Haruna Matsuda-Hirose; Yutaka Hatano; Motoi Takenaka; Hiroyuki Murota; Norito Katoh; Masutaka Furue
Journal:  Medicine (Baltimore)       Date:  2020-09-18       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.